SCHEMBL5136530

SCHEMBL5136530

CCCCn1c(-c2ccccc2)nc(-c2ccccc2)c1CN(Cc1ccc(C(=O)OC)cc1)Cc1cccc(OC)c1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
C5AR1 P21730 1/20 0.41
CNR2 P34972 1/20 0.41
TAS2R14 Q9NYV8 2/20 0.40
MEN1 O00255 1/20 0.40
KMT2A Q03164 1/20 0.40
PTGES O14684 1/20 0.40
ALOX5 P09917 1/20 0.40
TLR7 Q9NYK1 3/20 0.39
BCL2L1 Q07817 1/20 0.39
BAK1 Q16611 1/20 0.39
MEP1B Q16820 1/20 0.39
AGTR1 P30556 3/20 0.39
HSD17B2 P37059 2/20 0.38
TP53 P04637 1/20 0.38
LPAR1 Q92633 1/20 0.38
LPAR5 Q9H1C0 1/20 0.38
HDAC3 O15379 1/20 0.38
HDAC4 P56524 1/20 0.38
HDAC1 Q13547 1/20 0.38
HDAC7 Q8WUI4 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5137376 0.93 C5AR1 (0.42) C5AR1MEN1KMT2ATLR7AGTR1
SCHEMBL5135433 0.91 C5AR1 (0.46) C5AR1CNR2MEN1KMT2ATLR7
SCHEMBL5137576 0.90 TLR7 (0.47) C5AR1TLR7
SCHEMBL648419 0.90 C5AR1 (0.46) C5AR1CNR2TAS2R14MEN1KMT2A
SCHEMBL5137611 0.89 TAS2R14 (0.44) C5AR1CNR2TAS2R14MEN1KMT2A
SCHEMBL5137932 0.89 C5AR1 (0.44) C5AR1CNR2MEN1KMT2ATLR7
SCHEMBL648162 0.88 C5AR1 (0.48) C5AR1MEN1KMT2ATP53HDAC3
SCHEMBL5135950 0.87 LPAR1 (0.42) C5AR1TLR7AGTR1LPAR1LPAR5
SCHEMBL5135490 0.87 SIRT2 (0.43) C5AR1AGTR1TP53
SCHEMBL5135383 0.86 C5AR1 (0.45) C5AR1CNR2MEN1KMT2ATLR7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1490044-A4 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORP (US) 2008-04-16 EP disclosed
EP-1490044-A1 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORPORATION (US) 2004-12-29 EP disclosed
WO-2003084524-A1 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORPORATION (US) 2003-10-16 WO disclosed